Your session is about to expire
← Back to Search
MCS110 + BRAF/MEK Inhibitors for Melanoma
Study Summary
This trial is testing a combination of two targeted therapies, MCS110 and Dabrafenib, as a possible treatment for advanced melanoma patients with a BRAF V600E or BRAF V600K genetic mutation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 36 Patients • NCT01643850Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have samples of my tumor stored.My organ and bone marrow functions are normal.I haven't had chemotherapy, radiotherapy, major surgery, or experimental treatments recently.Signs of eye problems found during an eye exam.If you are enrolling for the phase II part of the trial, you need to have at least one specific visible sign of the disease that can be measured accurately.I have not taken BRAF or MEK inhibitors for my condition.I have brain metastases that have not been treated.I do not have any uncontrolled illnesses.I or someone in my family has long QT syndrome.All my side effects from previous cancer treatments are mild.I need to take medication that strongly affects liver enzymes.I am taking 10 mg or more of corticosteroids daily.I am 18 years old or older.I cannot swallow or keep down oral medication.I need to take medication that strongly affects liver enzymes.I have had or currently have issues with my eye's retina.My cancer progressed despite previous BRAF and MEK inhibitor treatments.My melanoma cannot be surgically removed, has spread, and does not respond to standard treatments.I still have side effects from cancer treatment that are not mild.I have had another type of cancer before.My cancer can be measured or seen on tests.Your heart's pumping ability is good, with a left ventricular ejection fraction (LVEF) of 50% or more.You have had allergic reactions to certain substances in the past.I am able to get out of my bed or chair and move around.Your heart's electrical activity should be within a certain range when measured by EKG.I have a digestive condition that affects how my body absorbs medication.You are expected to live for more than 8 weeks.I have been diagnosed with HIV.
- Group 1: MCS110+ Trametinib + Dabrafenib
- Group 2: MCS110 + Trametinib + Dabrafenib Phase 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you provide an overview of the preceding investigations involving MCS110?
"Currently, 96 research projects concerning MCS110 are underway with 6 of them in the third phase. Although most tests on this substance take place in Milano (MI), there are 5817 different locations providing trials for MCS110."
How many participants are enrolled in the current clinical trial?
"Unfortunately, this clinical trial is not looking to enrol patients at the moment. First posted on June 22nd 2018 and last updated December 8th 2021, it has since ceased recruitment; however there are 754 active trials related to melanoma and 96 for MCS110 that are still open to participants."
Are there any opportunities to partake in this research experiment?
"Per the information hosted on clinicaltrials.gov, it appears that this study has exhausted its recruitment and is not currently searching for candidates. The trial was first posted in June 2018 with a most recent update appearing in December 2021. Despite this conclusion, there are still 850 other trials which remain open to participants at present."
Share this study with friends
Copy Link
Messenger